MedTrace Logo

Dutasteride After Failure of Finasteride In the Management of Symptomatic Prostatic Enlargement/Hypertrophy (BPE/H)

NCT00382356 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2012-10-19

No results posted yet for this study

Summary

The study is to determine the safety and efficacy of Dutasteride in patients who have failed Finasteride therapy for their symptomatic benign prostatic enlargement/ hypertrophy (BPE/H).

Conditions

  • Benign Prostatic Hypertrophy

Interventions

DRUG

Dutasteride

once daily dosing of 0.5mg Dutasteride for 12 months

Sponsors & Collaborators

  • North Florida/South Georgia Veterans Health System

    lead OTHER

Principal Investigators

  • Unyime O Nseyo, M.D. · NF/SGVAHS

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-11-30
Primary Completion
2009-07-31
Completion
2009-07-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00382356 on ClinicalTrials.gov